Polyethylene glycol-phosphatidylethanolamine conjugate as a pulmonary nanocarrier for poorly soluble drug

The aim of this study was to investigate the potential of a polyethylene glycol-phosphatidylethanolamine conjugate (PEG<sub>2000</sub> -DSPE) to solubilize budesonide (BUD) for pulmonary delivery. The BUD-strictly stabilized phospholipid nanomicelles (SSMs) were prepared using the coprec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tan, Yvonne T.F., Abdulameer, Shaymaa A., Peh, Kok K., Darwis, Yusrida, Sahib, Mohanad N.
Formato: Articulo
Lenguaje:Inglés
Publicado: 2012
Materias:
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/8431
http://www.latamjpharm.org/resumenes/31/1/LAJOP_31_1_1_11.pdf
Aporte de:
Descripción
Sumario:The aim of this study was to investigate the potential of a polyethylene glycol-phosphatidylethanolamine conjugate (PEG<sub>2000</sub> -DSPE) to solubilize budesonide (BUD) for pulmonary delivery. The BUD-strictly stabilized phospholipid nanomicelles (SSMs) were prepared using the coprecipitation and reconstitution method and the physicochemical characteristics and pharmacodynamic duration of the BUD-SSMs were determined. The solubility of BUD was highly improved by at least 52 times its intrinsic solubility. The hydrodynamic particle size and zeta potential were 14.31 ± 1.40 nm and -46.61 ± 2.94 mV, respectively. The in vitro release of BUD from SSMs was completed within 6 days. Aerosolization of rehydrated BUD-SSMs with different nebulizers showed superior and significant aerodynamic characterizations compared to Pulmicort Respules® (PR). An in vivo study showed a significant reduction in the inflammatory cell counts of bronchoalveolar lavage fluid compared to PR. As a result, this study suggested that PEG<sub>2000</sub> -DSPE is a promising candidate as a budesonide carrier for pulmonary delivery.